A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation
暂无分享,去创建一个
Fan Zhang | Yiling Lu | Gordon B Mills | Zhenlin Ju | Samuel Leung | Bryan T Hennessy | David G Huntsman | G. Mills | S. Leung | D. Huntsman | Z. Ju | Kimberly C. Wiegand | S. Kalloger | M. Anglesio | M. Carey | B. Gilks | Yiling Lu | K. Stemke-Hale | B. Hennessy | Mollianne J. McGahren | Fan Zhang | Yemin Wang | Katherine Stemke-Hale | Sarah J. Finlayson | Michael S Anglesio | Kimberly C Wiegand | Yemin Wang | Mollianne McGahren | Steve E Kalloger | Sarah Finlayson | Blake Gilks | Mark S Carey | K. Stemke‐Hale
[1] Tomoyoshi Soga,et al. Oncometabolites: linking altered metabolism with cancer. , 2013, The Journal of clinical investigation.
[2] Yiling Lu,et al. Predicting time to ovarian carcinoma recurrence using protein markers. , 2013, The Journal of clinical investigation.
[3] Nicholas J. Wang,et al. Identification and Quantification of AKT Isoforms and Phosphoforms in Breast Cancer Using a Novel Nanofluidic Immunoassay* , 2013, Molecular & Cellular Proteomics.
[4] J. Hecht,et al. The clinicopathologic significance of p53 and BAF-250a (ARID1A) expression in clear cell carcinoma of the endometrium , 2013, Modern Pathology.
[5] N. Malats,et al. ARID1A Alterations Are Associated with FGFR3-Wild Type, Poor-Prognosis, Urothelial Bladder Tumors , 2013, PloS one.
[6] G. Mills,et al. Whole-exome sequencing combined with functional genomics reveals novel candidate driver cancer genes in endometrial cancer , 2012, Genome research.
[7] Gordon B Mills,et al. Proteomic classification of breast cancer. , 2012, Current drug targets.
[8] Thomas Zeng,et al. Use of mutation profiles to refine the classification of endometrial carcinomas , 2012, The Journal of pathology.
[9] R. Rustandi,et al. Applications of imaged capillary isoelectric focussing technique in development of biopharmaceutical glycoprotein‐based products , 2012, Electrophoresis.
[10] M. Pike,et al. Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of case–control studies , 2012, The Lancet. Oncology.
[11] I. Shih,et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high‐grade serous carcinoma—evidence supporting the clonal relationship of the two lesions , 2012, The Journal of pathology.
[12] Jeffrey R. Marks,et al. Loss of ARID1A-Associated Protein Expression is a Frequent Event in Clear Cell and Endometrioid Ovarian Cancers , 2012, International Journal of Gynecologic Cancer.
[13] Rosette Lidereau,et al. PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups , 2012, Breast Cancer Research.
[14] Tian-Li Wang,et al. ARID1A, a factor that promotes formation of SWI/SNF-mediated chromatin remodeling, is a tumor suppressor in gynecologic cancers. , 2011, Cancer research.
[15] J. Blaakaer,et al. The association between endometriosis and gynecological cancers and breast cancer: a review of epidemiological data. , 2011, Gynecologic oncology.
[16] G. Mills,et al. High frequency of PIK3R1 and PIK3R2 mutations in endometrial cancer elucidates a novel mechanism for regulation of PTEN protein stability. , 2011, Cancer discovery.
[17] H. Mackay,et al. Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010. , 2011, Gynecologic oncology.
[18] G. Mills,et al. PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast Cancer , 2011, Molecular Cancer Therapeutics.
[19] H. Kitchener,et al. First-Line Therapy in Ovarian Cancer Trials , 2011, International Journal of Gynecologic Cancer.
[20] Richard A. Moore,et al. ARID1A mutations in endometriosis-associated ovarian carcinomas. , 2010, The New England journal of medicine.
[21] Tian-Li Wang,et al. Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma , 2010, Science.
[22] G. Mills,et al. PI3K pathway-directed therapeutic strategies in cancer. , 2010, Current opinion in investigational drugs.
[23] Fan Zhang,et al. Functional Proteomic Analysis of Advanced Serous Ovarian Cancer Using Reverse Phase Protein Array: TGF-β Pathway Signaling Indicates Response to Primary Chemotherapy , 2010, Clinical Cancer Research.
[24] D. Huntsman,et al. Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas , 2010, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.
[25] A. Reuss,et al. Prognostic Relevance of Uncommon Ovarian Histology in Women With Stage III/IV Epithelial Ovarian Cancer , 2010, International Journal of Gynecologic Cancer.
[26] M. Takano,et al. Randomized Phase II Trial of Paclitaxel Plus Carboplatin Therapy Versus Irinotecan Plus Cisplatin Therapy as First-Line Chemotherapy for Clear Cell Adenocarcinoma of the Ovary: A JGOG Study , 2009, International Journal of Gynecologic Cancer.
[27] Yiling Lu,et al. AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. , 2009, Cancer cell.
[28] V. Velculescu,et al. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma. , 2009, The American journal of pathology.
[29] H. Lai,et al. PTEN promoter methylation and LOH of 10q22-23 locus in PTEN expression of ovarian clear cell adenocarcinomas. , 2009, Gynecologic oncology.
[30] S. Leung,et al. Ovarian Carcinoma Subtypes Are Different Diseases: Implications for Biomarker Studies , 2008, PLoS medicine.
[31] Zhi Hu,et al. An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. , 2008, Cancer research.
[32] R. Drapkin,et al. The distal fallopian tube: a new model for pelvic serous carcinogenesis , 2007, Current opinion in obstetrics & gynecology.
[33] G. Mills,et al. Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.
[34] P. Vercellini,et al. Molecular mechanisms and biological plausibility underlying the malignant transformation of endometriosis: a critical analysis. , 2006, Human reproduction update.
[35] Yiling Lu,et al. Exploiting the PI3K/AKT Pathway for Cancer Drug Discovery , 2005, Nature Reviews Drug Discovery.
[36] Wayne A. Phillips,et al. Mutation of the PIK3CA Gene in Ovarian and Breast Cancer , 2004, Cancer Research.
[37] R. Tibshirani,et al. Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[38] Leila Mohammadi,et al. BMC Cancer , 2001 .
[39] K. Ariyoshi,et al. Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study. , 2000, Gynecologic oncology.
[40] S. Silverberg,et al. Ovarian tumors associated with atypical endometriosis. , 1988, Human pathology.